ESPR - NASDAQ

Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc.

ESPRยทNASDAQ

$3.14

+0.32%
HealthcareBiotechnology

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$652.83M
EPS-0.1100
P/E Ratio-28.55
Earnings Date08/04/2026
Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc. Fair Value Envelope

ESPR ยท NASDAQ

Our analysis suggests that ESPR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.14, this represents a potential HIDDEN relative to our calculated worth for Esperion Therapeutics, Inc..

HIDDEN
Intrinsic Value
Current Price: $3.14

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$943.8M
+ Cash & Equivalents$167.9M
Firm Value-$776.0M
- Debt$548.0M
Equity Value-$1.3B
/ Shares Outstanding197,530,548B
DCF Value-$7
OVERVALUED BY 313%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$19.0M
-$27.7M
-$40.2M
-$58.5M
-$85.0M
-$123.6M
-$179.7M
-$261.3M
-$379.8M
-$552.2M
Maintenance CapEx
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
Owner Earnings
-$19.0M
-$27.7M
-$40.2M
-$58.5M
-$85.0M
-$123.6M
-$179.7M
-$261.3M
-$379.8M
-$552.2M
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$17.6M
-$23.7M
-$31.9M
-$43.0M
-$57.9M
-$77.9M
-$104.9M
-$141.2M
-$190.0M
-$255.8M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your ESPR research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.